中国原创肝病新药 填补丁肝治疗空白

Core Viewpoint - The approval of the innovative drug Libeweibeta monoclonal antibody for the treatment of chronic hepatitis D virus (HDV) infection marks a significant advancement in addressing the treatment gap for HDV in China, being the first monoclonal antibody approved globally for viral hepatitis [2][4]. Group 1: Drug Development and Approval - Libeweibeta monoclonal antibody was developed by a team led by Li Wenhui at the Beijing Institute of Life Sciences, representing a complete process of independent innovation from discovery to drug development [2][4]. - The drug targets the sodium-taurocholate co-transporting polypeptide (NTCP), identified as the common receptor for both hepatitis B virus (HBV) and HDV, which is crucial for the infection process [3][4]. - Clinical trials involving over 100 patients from China, Pakistan, and Mongolia demonstrated significant efficacy in viral response and liver function improvement, particularly in patients with liver cirrhosis [4][5]. Group 2: Future Directions and Goals - The company aims to expand its research pipeline beyond HDV and HBV to include cancer and other liver diseases, indicating a comprehensive drug development strategy [5]. - The ongoing clinical trials for a candidate drug (code HH-006) targeting hepatitis B are part of the broader goal to achieve a cure for hepatitis B, which remains a significant global health challenge [5].